Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
EMS Pharma, whose sister company Novamed bought Takeda’s Multilab last year, is reportedly the front-runner in the bidding process.
Takeda releases first post-Shire guidance; Indian generics makers are named in a price-fixing suit; Daiichi's quizartinib fails at FDA.
Ahead of an aesthetics market battle between Evolus' Jeuveau and Allergan's Botox, Evolus hosted doctors at a conference in Cancun.
Since Nestlé took full control of Galderma in 2014, its skin health unit never really lived up to expectations. And now, the company is bailing.
GlaxoSmithKline will unload an API plant to Thermo Fisher Scientific for €90 million. The U.S. company says it is glad to get it.
Civica Rx, a hospital group committed to manufacturing its own drugs, has picked the first drugs it will make and the contractor to make them.
With Novartis approaching jury trial for an alleged kickback scheme to docs, the feds seemed to have the company where they wanted it. Or maybe not.
When it comes to CLL, AZ is looking to push Imbruvica aside with newcomer Calquence. But based on some new data, one analyst doesn’t see it happening.
Cancer patients recount stories and offer advice in letters, looking back to when they were first diagnosed, in Merck’s new “With Love, Me” campaign.
AbbVie and Roche’s Venclexta may have recently hit a stumbling block—but in chronic lymphocytic leukemia, it’s rolling.
